Pharmacological options in the treatment of benign prostatic hyperplasia

J Med Chem. 1997 Apr 25;40(9):1293-315. doi: 10.1021/jm960697s.
No abstract available

Publication types

  • Review

MeSH terms

  • 5-alpha Reductase Inhibitors*
  • Adrenergic alpha-Antagonists / chemistry
  • Adrenergic alpha-Antagonists / metabolism
  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic alpha-Antagonists / therapeutic use*
  • Animals
  • Binding, Competitive
  • Controlled Clinical Trials as Topic
  • Endothelins / antagonists & inhibitors*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Humans
  • Male
  • Prostate / drug effects*
  • Prostate / metabolism
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Hyperplasia / metabolism
  • Receptors, Adrenergic, alpha / metabolism*
  • Structure-Activity Relationship

Substances

  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-Antagonists
  • Endothelins
  • Enzyme Inhibitors
  • Receptors, Adrenergic, alpha